학술논문
Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD
Document Type
article
Author
Katherine A. Pratte; Jeffrey L. Curtis; Katerina Kechris; David Couper; Michael H. Cho; Edwin K. Silverman; Dawn L. DeMeo; Frank C. Sciurba; Yingze Zhang; Victor E. Ortega; Wanda K. O’Neal; Lucas A. Gillenwater; David A. Lynch; Eric A. Hoffman; John D. Newell; Alejandro P. Comellas; Peter J. Castaldi; Bruce E. Miller; Simon D. Pouwels; Nick H. T. ten Hacken; Rainer Bischoff; Frank Klont; Prescott G. Woodruff; Robert Paine; R. Graham Barr; John Hoidal; Claire M. Doerschuk; Jean-Paul Charbonnier; Ruby Sung; Nicholas Locantore; John G. Yonchuk; Sean Jacobson; Ruth Tal-singer; Debbie Merrill; Russell P. Bowler
Source
Respiratory Research, Vol 22, Iss 1, Pp 1-13 (2021)
Subject
Language
English
ISSN
1465-993X
Abstract
Abstract Background Soluble receptor for advanced glycation end products (sRAGE) is a proposed emphysema and airflow obstruction biomarker; however, previous publications have shown inconsistent associations and only one study has investigate the association between sRAGE and emphysema. No cohorts have examined the association between sRAGE and progressive decline of lung function. There have also been no evaluation of assay compatibility, receiver operating characteristics, and little examination of the effect of genetic variability in non-white population. This manuscript addresses these deficiencies and introduces novel data from Pittsburgh COPD SCCOR and as well as novel work on airflow obstruction. A meta-analysis is used to quantify sRAGE associations with clinical phenotypes. Methods sRAGE was measured in four independent longitudinal cohorts on different analytic assays: COPDGene (n = 1443); SPIROMICS (n = 1623); ECLIPSE (n = 2349); Pittsburgh COPD SCCOR (n = 399). We constructed adjusted linear mixed models to determine associations of sRAGE with baseline and follow up forced expiratory volume at one second (FEV1) and emphysema by quantitative high-resolution CT lung density at the 15th percentile (adjusted for total lung capacity). Results Lower plasma or serum sRAGE values were associated with a COPD diagnosis (P